Edaravone: A new drug approved for ALS

Area of Science:

• Neurodegenerative diseases
• Drug discovery and development
• Amyotrophic lateral sclerosis (ALS) research

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive, fatal adult-onset neurodegenerative disease.
• The history of ALS drug discovery is marked by significant challenges and lengthy intervals between therapeutic advancements.
• Historically, few pharmaceutical interventions have demonstrated efficacy in altering the course of ALS progression.

Purpose of the Study:

• To review the historical landscape of drug discovery for amyotrophic lateral sclerosis (ALS).
• To highlight the significant time lag between the approval of early therapeutic agents and the emergence of new effective treatments for ALS.
• To contextualize the limited success in developing drugs that can alter ALS progression.

Main Methods:

• Literature review of FDA-approved drugs for amyotrophic lateral sclerosis (ALS).
• Analysis of historical timelines for drug approvals related to ALS treatment.
• Examination of the pharmacological classes and mechanisms of action for approved ALS therapies.

Main Results:

• The FDA approval of Riluzole, an anti-excitotoxic drug, occurred 22 years prior to the next successful therapeutic agent.
• Edaravone, an antioxidant, represents the second drug found effective in altering ALS progression.
• The long interval between Riluzole and Edaravone underscores the difficulties in ALS drug development.

Conclusions:

• Drug discovery for amyotrophic lateral sclerosis (ALS) has historically faced significant hurdles.
• The development of effective treatments for ALS requires sustained research and innovation.
• The limited number of approved drugs highlights the unmet medical need in ALS treatment.